

## Chapter 2 - endnotes

1. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, <http://www.unodc.org/unodc/en/treaties/single-convention.html> & UN Convention on Psychotropic Drugs of 1971, <https://www.unodc.org/unodc/en/treaties/psychotropics.html>
2. Hallam, C. Bewley-Taylor, D. & Jelsma, M. (2014), *Scheduling in the international drug control system* (International Drug Policy Consortium & Transnational Institute), <http://idpc.net/publications/2014/06/scheduling-in-the-international-drug-control-system>
3. Nutt, D. King, L.A., Saulsbury, W. & Blackmore, C. (2007), 'Development of a rational scale to assess the harm of drugs of potential misuse', *The Lancet*, **369**(9566): 1047-1053, <http://www.thelancet.com/journals/lancet/article/PIIS0140673607604644/abstract>. This research was reviewed in 2010, see: Nutt, D., King, L.A. & Phillips, L.D. (November 2010), 'Drug harms in the UK: A multicriteria decision analysis', *The Lancet*, **376**(9752): 1558-1565, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961462-6/fulltext#article\\_upsell](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961462-6/fulltext#article_upsell). However, even the scientific methodology and ranking proposed by Nutt et al has been questioned, highlighting the complexity of capturing the level of harms related to drug using behaviours and environments, the personal and social risks of particular groups of people who use drugs, and the broader socio-cultural context in which drug use takes place. See: Rolles, S. & Measham, F. (July 2011), 'Questioning the method and utility of ranking drug harms in drug policy', *International Journal of Drug Policy*, **22**(4): 243-246, [http://www.ijdp.org/article/S0955-3959\(11\)00058-2/abstract](http://www.ijdp.org/article/S0955-3959(11)00058-2/abstract)
4. The revised 2010 ranking of harm places ketamine lower in the scale of harms, after alcohol, heroin, crack, methamphetamine, tobacco, cannabis and GHB. See: Nutt, D., King, L.A. & Phillips, L.D. (November 2010), 'Drug harms in the UK: A multicriteria decision analysis', *The Lancet*, **376**(9752): 1558-1565, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961462-6/fulltext#article\\_upsell](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961462-6/fulltext#article_upsell)
5. Figure taken from: West Africa Commission on Drugs (2014), *Not just in transit: An independent report of the West Africa Commission on Drugs*, <http://www.wacommissionondrugs.org/report/>
6. Commission on Narcotic Drugs (16 December 2014), *Changes in the scope of control of substances, Note by the Secretariat*, E/CN.7/2015/7, <http://www.un.org/Docs/journal/asp/ws.asp?m=E/CN.7/2015/7>
7. Scholten, W. (2014), *Factsheet on the proposal to discuss international scheduling of ketamine at the 58th CND*, <http://idpc.net/publications/2015/01/fact-sheet-on-the-proposal-to-discuss-international-scheduling-of-ketamine-at-the-58th-cnd>
8. Co-ordination Centre for the Assessment and Monitoring New Drugs (November 2007), *Riscoschatting qat 2007* (Coördinatiepunt Assessment en Monitoring nieuwe drugs), [http://www.rivm.nl/bibliotheek/digitaaldepot/CAM\\_qat\\_riscoschattingsrapport\\_2007.pdf](http://www.rivm.nl/bibliotheek/digitaaldepot/CAM_qat_riscoschattingsrapport_2007.pdf)
9. De Jonge, M. & Van der Veen, C. (2011), *Qatgebruik onder Somaliërs in Nederland* (Utrecht: Trimbos Instituut)
10. Advisory Council on the Misuse of Drugs (January 2013), *Khat: A review of its potential harms to the individual and communities in the UK*, [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/144120/report-2013.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/144120/report-2013.pdf)
11. BBC News (3 July 2013), *Herbal stimulant khat to be banned*, <http://www.bbc.com/news/uk-23163017>
12. Travis, A. (29 November 2013), 'MPs urge Theresa May to reverse qat ban', *The Guardian*, <http://www.theguardian.com/politics/2013/nov/29/mps-urge-theresa-may-reverse-qat-ban>
13. UK Home Office (2014), *Khat fact sheet for England & Wales*, [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/341917/Khat\\_leaflet\\_A4\\_v12\\_2\\_.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/341917/Khat_leaflet_A4_v12_2_.pdf)
14. World Health Organisation (2012), *WHO Expert Committee on Drug Dependence – Thirty-fifth Report*, WHO Technical Report Series 973, [http://apps.who.int/iris/bitstream/10665/77747/1/WHO\\_trs\\_973\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/77747/1/WHO_trs_973_eng.pdf?ua=1)
15. Durjava, L. & Southwell, M. (29 September 2013), 'Ketamine: Living in dreams, managing the realities', *Open Democracy*, <https://www.opendemocracy.net/lana-durjava-mat-southwell/ketamine-living-in-dreams-managing-realities>
16. World Health Organisation (April 2015), *WHO Model list of essential medicines, 19<sup>th</sup> list*, [http://www.who.int/selection\\_medicines/committees/expert/20/EML\\_2015\\_FINAL\\_amended\\_AUG2015.pdf?ua=1](http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1)
17. Advisory Council on the Misuse of Drugs, UK government, <https://www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs>
18. Advisory Council on the Misuse of Drugs (2008), *Cannabis: Classification and public health* (London: Home Office), [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/119174/acmd-cannabis-report-2008.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119174/acmd-cannabis-report-2008.pdf)
19. House of Commons Hansard Debates for 9<sup>th</sup> February 2009, Column 1094, <http://www.publications.parliament.uk/pa/cm200809/cmhansrd/cm090209/debtext/90209-0001.htm>
20. David Nutt (2009), *Estimating drug harms – A risky business?* (London: Centre for Crime and Justice Studies), <http://www.crimeandjustice.org.uk/publications/estimating-drug-harms-risky-business>
21. Mark Easton (2009), 'Nutt gets the sack', *BBC Blog*, [http://www.bbc.co.uk/blogs/thereporters/markeaston/2009/10/nutt\\_gets\\_the\\_sack.html](http://www.bbc.co.uk/blogs/thereporters/markeaston/2009/10/nutt_gets_the_sack.html)
22. BZP in 2007 and mephedrone in 2010
23. European Commission (11 July 2011), *Report from the Commission on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances*, <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2011:0430:FIN:en:PDF>; European Commission (11 July 2011), *Commission Staff Working Paper on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, Accompanying the Document Report from the Commission on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances*, <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SEC:2011:0912:FIN:en:PDF>
24. See: Europa Press releases database (17 September 2013), *European Commission takes decisive action against legal highs*, [http://europa.eu/rapid/press-release\\_IP-13-837\\_en.htm](http://europa.eu/rapid/press-release_IP-13-837_en.htm)
25. Ibid
26. Ibid
27. Ibid
28. For example, in January 2014, the UK announced that it would opt out of the proposed system ostensibly because it strongly disputes the EU claim that 20% of 'legal highs' have 'legitimate commercial and industrial uses'. See: Travis, A. (13 January 2014), 'Legal highs: UK to opt out of new EU regulation regime', *The Guardian*, <http://www.theguardian.com/world/2014/jan/13/legal-highs-uk-opt-out-eu-regulation-regime>
29. Vasconi, C. (September 2013), *Expert Seminar – Where next for Europe on drug policy reform? IDPC-TNI-SICAD, Lisbon, Portugal, 20<sup>th</sup> to 21<sup>st</sup> June 2013*, p. 15, [http://www.tni.org/sites/www.tni.org/files/download/expert\\_seminar\\_in\\_lisbon\\_final.pdf](http://www.tni.org/sites/www.tni.org/files/download/expert_seminar_in_lisbon_final.pdf)
30. See: McCullough, Wood, J. & Zorn, R. (September 2013), *New Zealand's psychoactive substances legislation* (London: International Drug Policy Consortium & New Zealand Drug Foundation), <http://idpc.net/publications/2013/09/idpc-briefing-paper-new-zealand-s-psychoactive-substances-legislation>; New Zealand Drug Foundation (2013), *Briefing and submission guide on the Psychoactive Substances Bill*, [https://www.drugfoundation.org.nz/sites/default/files/NZ%20Drug%20Foundation%20-%20Psychoactive%20Substances%20Bill%20submission%20guide\\_0.pdf](https://www.drugfoundation.org.nz/sites/default/files/NZ%20Drug%20Foundation%20-%20Psychoactive%20Substances%20Bill%20submission%20guide_0.pdf)
31. <http://www.legislation.govt.nz/act/public/2013/0053/latest/DLM5042921.html?src=qs>
32. See: McCullough, Wood, J. & Zorn, R. (September 2013), *New Zealand's psychoactive substances legislation* (London: International Drug Policy Consortium & New Zealand Drug Foundation), p. 7,

- <http://idpc.net/publications/2013/09/idpc-briefing-paper-new-zealand-s-psychoactive-substances-legislation>
33. World Health Organisation (1985), *WHO Expert Committee on Drug Dependence: Twenty-Second Report*, TRS 729, [http://apps.who.int/iris/bitstream/10665/39635/1/WHO\\_TRS\\_729.pdf](http://apps.who.int/iris/bitstream/10665/39635/1/WHO_TRS_729.pdf)
  34. World Health Organisation (2006), *Assessment of khat (Catha edulis Forsk)*, WHO Expert Committee on Drug Dependence, 34<sup>th</sup> ECDD 2006/4.4, [http://www.who.int/medicines/areas/quality\\_safety/4.4KhatCritReview.pdf](http://www.who.int/medicines/areas/quality_safety/4.4KhatCritReview.pdf)
  35. See: World Health Organisation (2011), *Ensuring balance in national policies on controlled substances*, [http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175_eng.pdf)
  36. See: International Narcotics Control Board & World Health Organisation (2012), *Estimating requirements for substances under international control*, [https://www.incb.org/documents/Narcotic-Drugs/Guidelines/estimating\\_requirements/NAR\\_Guide\\_on\\_Estimating\\_EN\\_Ebook.pdf](https://www.incb.org/documents/Narcotic-Drugs/Guidelines/estimating_requirements/NAR_Guide_on_Estimating_EN_Ebook.pdf)
  37. Nutt, D. (27 January 2015), 'Illegal drugs laws: Clearing a 50-year-old obstacle to research', *PLOS Biology*, **13**(1): e1002047. doi:10.1371/journal.pbio.1002047, <http://journals.plos.org/plos-biology/article?id=10.1371/journal.pbio.1002047>
  38. World Health Organisation (April 2015), *WHO Model list of essential medicines, 19<sup>th</sup> list*, [http://www.who.int/selection\\_medicines/committees/expert/20/EML\\_2015\\_FINAL\\_amended\\_AUG2015.pdf?ua=1](http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1)
  39. Ibid
  40. See: World Health Organisation (April 2015), *WHO Model list of essential medicines, 19<sup>th</sup> list*, [http://www.who.int/selection\\_medicines/committees/expert/20/EML\\_2015\\_FINAL\\_amended\\_AUG2015.pdf?ua=1](http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1); World Health Organisation (April 2015), *WHO model list of essential medicines for children, 5<sup>th</sup> list*, [http://www.who.int/entity/medicines/publications/essentialmedicines/EMLc\\_2015\\_FINAL\\_amended\\_AUG2015.pdf?ua=1](http://www.who.int/entity/medicines/publications/essentialmedicines/EMLc_2015_FINAL_amended_AUG2015.pdf?ua=1)
  41. World Health Organisation (April 2012), *Briefing note – Access to controlled medications programme: Improving access to medications controlled under international drug conventions*, [http://www.who.int/medicines/areas/quality\\_safety/ACMP\\_BrNote\\_Genr\\_EN\\_Apr2012.pdf?ua=1](http://www.who.int/medicines/areas/quality_safety/ACMP_BrNote_Genr_EN_Apr2012.pdf?ua=1)
  42. Global Commission on Drug Policy (October 2015), *The negative impact of drug control on public health: The global crisis of avoidable pain*, p. 22, <http://www.globalcommissionondrugs.org/reports/>
  43. Ibid
  44. International Narcotics Control Board (2011), *Report of the International Narcotics Control Board on the availability of internationally controlled drugs: Ensuring adequate access for medical and scientific purposes*, [http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10\\_availability\\_English.pdf](http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf); International Narcotics Control Board (1995), *Availability of opiates for medical needs: Report of the International Narcotics Control Board for 1995*, p. 1, <https://dl.dropboxusercontent.com/u/64663568/library/incb-availability-of-opiates-for-medical-purposes-1995.pdf>
  45. 1961 Single Convention on Narcotic Drugs, articles 30(1)(b)(i), 30(1)(b)(ii), 30(2)(b)(i) and 34(b)
  46. See: article 39 of the 1961 Single Convention on Narcotic Drugs and article 23 of the 1971 Convention on Psychotropic Substances
  47. World Health Organisation (2011), *Ensuring balance in national policies on controlled substances*, [http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175_eng.pdf)
  48. International Narcotics Control Board (2015), *INCB Annual Report for 2014*, [https://www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR\\_2014.pdf](https://www.incb.org/documents/Publications/AnnualReports/AR2014/English/AR_2014.pdf); International Narcotics Control Board (2011), *Report of the International Narcotics Control Board on the availability of internationally controlled drugs: Ensuring adequate access for medical and scientific purposes*, [http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10\\_availability\\_English.pdf](http://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf)
  49. General Assembly (30 March 2010), *Resolution adopted by the General Assembly on 18 December 2009 – 64/182. International cooperation against the world drug problem*, A/RES/64/192, <http://www.un.org/Docs/journal/asp/ws.asp?m=A/RES/64/182>; Commission on Narcotic Drugs (2010), *CND Resolution 53/4: Promoting adequate availability of internationally controlled licit drugs for medical and scientific purposes while preventing their diversion and abuse*, [https://www.unodc.org/documents/commissions/CND/Drug\\_Resolutions/2010-2019/2010/CND\\_Res-53-4.pdf](https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2010-2019/2010/CND_Res-53-4.pdf)
  50. United Nations Office on Drugs and Crime (2011), *Ensuring availability of controlled medications for the relief of pain and preventing diversion and abuse*, [https://www.unodc.org/docs/treatment/Pain/Ensuring\\_availability\\_of\\_controlled\\_medications\\_FINAL\\_15\\_March\\_CND\\_version.pdf](https://www.unodc.org/docs/treatment/Pain/Ensuring_availability_of_controlled_medications_FINAL_15_March_CND_version.pdf)
  51. World Health Assembly (2014), *Strengthening of palliative care as a component of comprehensive care throughout the life course*, WHA67.19, [http://apps.who.int/gb/ebwha/pdf\\_files/WHA67/A67\\_R19-en.pdf](http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R19-en.pdf)
  52. World Health Organisation (2011), *Ensuring balance in national policies on controlled substances*, [http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44519/1/9789241564175_eng.pdf)
  53. Human Rights Watch (June 2015), *Mexico: Breakthrough for pain treatment modernized system for prescribing strong medicines*, <https://www.hrw.org/news/2015/06/15/mexico-breakthrough-pain-treatment>
  54. Human Rights Watch (October 2014), *Care when there is no cure – Ensuring the right to palliative care in Mexico*, <https://www.hrw.org/report/2014/10/28/care-when-there-no-cure/ensuring-right-palliative-care-mexico>
  55. Human Rights Watch (September 2010), *Needless pain government failure to provide palliative care for children in Kenya*, <https://www.hrw.org/report/2010/09/09/needless-pain/government-failure-provide-palliative-care-children-kenya>
  56. Communication with Dr. Zipporah Ali, Executive Director of the Kenya Hospice and Palliative Care Association, September 2015
  57. The 2015 UNODC World Drug Report acknowledges that the global prevalence of drug use has overall remained stable. See: United Nations Office on Drugs and Crime (2015), *UNODC World Drug Report 2015*, p. 11, <http://www.unodc.org/wdr2015/>
  58. See, for instance: Werb, D., Mills, E.J., DeBeck, K., Montaner, J.S.G. & Wood, E. (2011), 'The effectiveness of anti-illicit-drug public-service announcements: A systematic review and meta-analysis', *Journal of Epidemiology & Community Health*, **65**(10): 834-840, <http://www.ncbi.nlm.nih.gov/pubmed/21558482>
  59. United Nations Office on Drugs and Crime, *Prevention*, <http://www.unodc.org/unodc/en/prevention/>; Canadian Centre on Substance Abuse (2013), *A case for investing in youth substance abuse prevention*, <http://www.ccsa.ca/Resource%20Library/2012-ccsa-Investing-in-youth-substance-abuse-prevention-en.pdf>; Miller, T., & Hendrie, D. (2009), *Substance abuse prevention dollars and cents: A cost-benefit analysis* (Center for Substance Abuse Prevention), <http://store.samhsa.gov/shin/content/SMA07-4298/SMA07-4298.pdf>; Lee, S., Drake, E., Pennucci, A., Miller, M. & Anderson, L. (2012), *Return on investment: Evidence-based options to improve statewide outcomes* (Olympia: Washington State Institute for Public Policy)
  60. US Government Accountability Office (January 2003), *Youth illicit drug use prevention: DARE long-term evaluations and federal efforts to identify effective programs*, <http://www.gao.gov/products/GAO-03-172R>; Rosenbaum, D.P. & Hanson, G.S. (1998), 'Assessing the effects of school-based drug education: A six year multilevel analysis of Project DARE', *Journal of Research in Crime and Delinquency*, **35**(4): 381, <http://jrc.sagepub.com/content/35/4/381.abstract>; Lynam, D.R., et al. (1999), 'Project DARE: No effects at 10-year follow-up', *Journal of Consulting and Clinical Psychology*, **67**(4): 590, <http://barkingduck.net/ehayes/essays/ccp674590.html>. A similar campaign in the UK entitled 'Heroin Screws You Up', aimed to show the adverse impacts of heroin on physical appearance, was also counter-productive and led to increases in heroin use in the country. See: Hinkley, K. (21 October 2014), '5 ridiculous anti-drugs posters', *TalkingDrugs*, <http://www.talkingdrugs.org/5-anti-drugs-campaigns>
  61. European Monitoring Centre on Drugs and Drug Addiction (2011), *European drug prevention quality standards*, <http://www.emcdda.europa.eu/publications/manuals/prevention-standards>
  62. United Nations Office on Drugs and Crime (2013), *International standards on drug use prevention*, <https://www.unodc.org/unodc/en/prevention/prevention-standards.html>

63. See: <http://www.emcdda.europa.eu/topics/prevention>
64. Hawks, D., Scott, K., & McBride, M. (2002), *Prevention of psychoactive substance use: A selected review of what works in the area of prevention* (Geneva: World Health Organisation); Orwin, R., et al. (2004), *Evaluation of the national youth anti-drug media campaign: 2004 report of findings* (Washington DC: National Institute on Drug Abuse), <http://archives.drugabuse.gov/initiatives/westat/#reports>
65. Hawks, D., Scott, K., & McBride, M. (2002), *Prevention of psychoactive substance use: A selected review of what works in the area of prevention* (Geneva: World Health Organisation); European Monitoring Centre on Drugs and Drug Addiction, *EMCDDA best practice in drug interventions*, <http://www.emcdda.europa.eu/best-practice#view-start>
66. Babor, T., et al. (2010), *Drug policy and the public good* (Oxford: Oxford University Press); See, also the impacts of the Coping Power Programme in the Netherlands: [http://www.emcdda.europa.eu/modules/wbs/dsp\\_print\\_project\\_description.cfm?project\\_id=NL0801](http://www.emcdda.europa.eu/modules/wbs/dsp_print_project_description.cfm?project_id=NL0801), or that of the 'EmPeCemos' (Emotions, Thoughts and Feelings for a healthy development) programme in Spain: [http://www.emcdda.europa.eu/modules/wbs/dsp\\_print\\_project\\_description.cfm?project\\_id=ES\\_03](http://www.emcdda.europa.eu/modules/wbs/dsp_print_project_description.cfm?project_id=ES_03)
67. More information about Unplugged, as well as the tools, activities and various projects, can be found on the EU-Dap website: [www.eudap.net](http://www.eudap.net)
68. See, for instance: Van der Kreeft, P. et al (2009), 'Unplugged': A new European school programme against substance abuse', *Drugs: education, prevention and policy*, **16** (2): 167-181; Faggiano, F. et al (2010), 'The effectiveness of a school-based substance abuse prevention program: 18-Month follow-up of the EU-Dap cluster randomized controlled trial', *Drug and Alcohol Dependence*, **108**: 56-64
69. European Monitoring Centre on Drugs and Drug Addiction, *Searching family treasure summary*, [http://www.emcdda.europa.eu/html.cfm/index52035EN.html?project\\_id=5136&tab=overview](http://www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5136&tab=overview)
70. European Monitoring Centre on Drugs and Drug Addiction, *Searching family treasure – Executive summary*, [http://www.emcdda.europa.eu/modules/wbs/dsp\\_print\\_project\\_description.cfm?project\\_id=5136](http://www.emcdda.europa.eu/modules/wbs/dsp_print_project_description.cfm?project_id=5136)
71. European Monitoring Centre on Drugs and Drug Addiction, *Searching family treasure summary*, [http://www.emcdda.europa.eu/html.cfm/index52035EN.html?project\\_id=5136&tab=overview](http://www.emcdda.europa.eu/html.cfm/index52035EN.html?project_id=5136&tab=overview)
72. Ibid
73. Instituto da Droga e da Toxicodependência (2012), *Prevenção das toxicodependências em Grupos Vulneráveis – Catálogo de Boas Práticas*, [http://www.sicad.pt/PT/Intervencao/PrevencaoMais/Documents/Cat%C3%A1logo\\_de\\_Boas\\_Pr%C3%A1ticas\\_2012.pdf](http://www.sicad.pt/PT/Intervencao/PrevencaoMais/Documents/Cat%C3%A1logo_de_Boas_Pr%C3%A1ticas_2012.pdf)
74. Room, R. (2006), *The effectiveness and impact of environmental strategies of prevention: Lessons from legal psychoactive substances, and their applicability to illicit drugs*, [http://www.emcdda.europa.eu/attachments.cfm/att\\_44273\\_EN\\_History%20and%20concepts%20of%20environmental%20strategies%20-%20Robin%20Room.pdf](http://www.emcdda.europa.eu/attachments.cfm/att_44273_EN_History%20and%20concepts%20of%20environmental%20strategies%20-%20Robin%20Room.pdf)
75. European Monitoring Centre on Drugs and Drug Addiction (2011), *European drug prevention quality standards*, <http://www.emcdda.europa.eu/publications/manuals/prevention-standards>
76. See: United Nations Office on Drugs and Crime (2013), *International standards on drug use prevention*, <http://www.unodc.org/unodc/en/prevention/prevention-standards.html>; European Monitoring Centre on Drugs and Drug Addiction (2011), *European drug prevention quality standards*, <http://www.emcdda.europa.eu/publications/manuals/prevention-standards>
77. These key points and examples of quality standards presented below are drawn from: European Monitoring Centre on Drugs and Drug Addiction (2011), *European drug prevention quality standards*, <http://www.emcdda.europa.eu/publications/manuals/prevention-standards>
78. European Monitoring Centre on Drugs and Drug Addiction (2011), *European drug prevention quality standards*, <http://www.emcdda.europa.eu/publications/manuals/prevention-standards>
79. Harm Reduction International (2010), *What is harm reduction? A position statement from the International Harm Reduction Association*, <http://www.ihra.net/what-is-harm-reduction>
80. Ibid
81. United Nations Office on Drugs and Crime (2015), *UNODC World Drug Report 2015*, <http://www.unodc.org/wdr2015/>
82. Ibid
83. Ibid
84. Harm Reduction International (2015), *A global review of the harm reduction response to amphetamines: A 2015 update*, [http://www.ihra.net/files/2015/10/18/AmphetaminesReport\\_Oct2015\\_web.pdf](http://www.ihra.net/files/2015/10/18/AmphetaminesReport_Oct2015_web.pdf)
85. See, for example: <http://bookofauthorities.info/>
86. Harm Reduction International (2014), *The global state of harm reduction 2014*, <http://www.ihra.net/contents/1524>
87. Mathers, B.M., et al (2010), 'HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage', *The Lancet*, **375**(9719): 1014-1028, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60232-2/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60232-2/abstract)
88. Harm Reduction International, International Drug Policy Consortium & International HIV/AIDS Alliance (2014), *The funding crisis for harm reduction*, [www.ihra.net/files/2014/09/22/Funding\\_report\\_2014.pdf](http://www.ihra.net/files/2014/09/22/Funding_report_2014.pdf)
89. Most notably Russia, where more than one-third of people who inject drugs are living with HIV. See: Global Commission on Drug Policy (2011), *War on drugs*, [http://www.globalcommissionondrugs.org/wp-content/themes/gcdp\\_v1/pdf/Global\\_Commission\\_Report\\_English.pdf](http://www.globalcommissionondrugs.org/wp-content/themes/gcdp_v1/pdf/Global_Commission_Report_English.pdf)
90. World Health Organisation (2014), *Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations*, <http://www.who.int/hiv/pub/guidelines/keypopulations/en/>
91. Shaw, G. (2014), *Independent evaluation: Community Action on Harm Reduction (CAHR)*, <http://www.cahrproject.org/resource/independent-evaluation-cahr/>
92. For more information, visit the CAHR website: [www.cahrproject.org](http://www.cahrproject.org)
93. International Conference on Drug Policy and Policing (2013), *Frankfurt principles on drug law enforcement*, <https://www.opensocietyfoundations.org/briefing-papers/frankfurt-principles>
94. World Health Organisation, United Nations Office on Drugs and Crime & Joint United Nations Programme on HIV/AIDS (2009), *Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users*, <http://www.who.int/hiv/pub/idu/targetsetting/en/>. This document has since been updated in 2012: [http://www.who.int/hiv/pub/idu/targets\\_universal\\_access/en/](http://www.who.int/hiv/pub/idu/targets_universal_access/en/)
95. Harm Reduction International (2015), *A global review of the harm reduction response to amphetamines: A 2015 update*, [http://www.ihra.net/files/2015/10/18/AmphetaminesReport\\_Oct2015\\_web.pdf](http://www.ihra.net/files/2015/10/18/AmphetaminesReport_Oct2015_web.pdf)
96. United Nations Office on Drugs and Crime & World Health Organisation (2013), *Opioid overdose: Preventing and reducing opioid overdose mortality*, <https://www.unodc.org/docs/treatment/overdose.pdf>
97. World Health Organisation (2004), *Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users*, <http://www.who.int/hiv/pub/idu/e4a-needle/en/>
98. Roux, P., et al. (2009), 'Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment', *Clinical Infectious Diseases*, **49**(9): 1433–1440, <http://cid.oxfordjournals.org/content/49/9/1433.full>
99. Deiss, R.G., Rodwell, T.C. & Garfein, R.S. (2009), 'Tuberculosis and illicit drug use: Review and update', *Clinical Infectious Diseases*, **48**(1): 72–82, <http://www.ncbi.nlm.nih.gov/pubmed/19046064>
100. World Health Organisation, United Nations Office on Drugs and Crime & Joint United Nations Programme on HIV/AIDS (2004), *Position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention*, [http://www.who.int/substance\\_abuse/publications/en/PositionPaper\\_English.pdf](http://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf)

101. World Health Organisation (2014), *Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations*, <http://www.who.int/hiv/pub/guidelines/keypopulations/en/>
102. Wolfe, D., Carrier, M.P. & Shepard, D. (2010), 'Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward', *The Lancet*, **376**(9738): 355–366, [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(10\)60832-X.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(10)60832-X.pdf)
103. Wolfe, D. & Cohen, J. (2010), 'Human rights and HIV prevention, treatment, and care for people who inject drugs: Key principles and research needs', *Journal of Acquired Immune Deficiency Syndromes*, **55**(S1): S56–S62, <http://www.ncbi.nlm.nih.gov/pubmed/21045602>
104. Hellard, M., Sacks-Davis, R. & Gold, J. (2009), 'Hepatitis C treatment for injection drug users: A review of the available evidence', *Clinical Infectious Diseases*, **49**(4): 561–573, <http://www.ncbi.nlm.nih.gov/pubmed/19589081>
105. New York City Department of Health and Mental Hygiene (2010), 'Illicit drug use in New York City', *NYC Vital Signs*, **9**(1), <http://www.nyc.gov/html/doh/downloads/pdf/survey/survey-2009drugod.pdf>
106. Interventions 10 to 16 were elaborated as part of a broader package of interventions that also include the 9 UN interventions in: International HIV/AIDS Alliance (2010), *Good practice guide: HIV and drug use*, [http://www.aidsalliance.org/assets/000/000/383/454-Good-practice-guide-HIV-and-drug-use\\_original.pdf](http://www.aidsalliance.org/assets/000/000/383/454-Good-practice-guide-HIV-and-drug-use_original.pdf)
107. International Drug Policy Consortium & Eurasian Harm Reduction Network (2014), *Drug policy training toolkit: Facilitation guide*, <http://idpc.net/policy-advocacy/training-toolkit>
108. Kessler, R.C., et al. (1994), 'Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey', *Archives of General Psychiatry*, **51**: 8-19; Regier, D.A., et al. (1990), 'Comorbidity of mental disorders with alcohol and other drug abuse', *Journal of the American Medical Association*, **264**: 2511-2518, <http://jama.ama-assn.org/content/264/19/2511.abstract>
109. For more information, visit the Support. Don't Punish campaign website: <http://supportdontpunish.org/>
110. For example: <https://www.facebook.com/supportdontpunish> and <https://twitter.com/sdpcampaign>
111. For more information, visit: <http://supportdontpunish.org/photo-project>
112. For more information, visit: <http://supportdontpunish.org/day-of-action-2015/>
113. See: <http://www.leshrc.org/>
114. See the Release website at: [www.release.org.uk](http://www.release.org.uk)
115. Vancouver Coastal Health (2006), *Crystal Clear: A practical guide for working with peers and youth*, [http://www.vancouveragreement.ca/wp-content/uploads/2006\\_Crystal-Clear-A-Practical-Guide.pdf](http://www.vancouveragreement.ca/wp-content/uploads/2006_Crystal-Clear-A-Practical-Guide.pdf)
116. IDPC also recommends interventions 17 to 21 as part of a comprehensive harm reduction approach – this list is not exhaustive. For more recommendations on harm reduction targeting people who use amphetamines, see: Harm Reduction International (2015), *A global review of the harm reduction response to amphetamines: A 2015 update*, [http://www.ihra.net/files/2015/10/18/AmphetaminesReport\\_Oct2015\\_web.pdf](http://www.ihra.net/files/2015/10/18/AmphetaminesReport_Oct2015_web.pdf)
117. European Monitoring Centre for Drugs and Drug Addiction (2015), *Drug consumption rooms: An overview of provision and evidence*, <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
118. Marshall, B.D.L., Milloy, M.J., Wood, E., Montaner, J.S.G. & Kerr, T. (2011), 'Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study', *The Lancet*, **377**(9775): 1429-1437, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)62353-7/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62353-7/abstract)
119. United Nations Office on Drugs and Crime, UN Women, World Health Organisation & International Network of People who Use Drugs (2014), *Women who inject drugs and HIV: Addressing specific needs*, [www.unodc.org/documents/hiv-aids/publications/WOMEN\\_POLICY\\_BRIEF2014.pdf](http://www.unodc.org/documents/hiv-aids/publications/WOMEN_POLICY_BRIEF2014.pdf)
120. See: Croisier, J. (2 December 2014), 'Bragos Abertos in Sao Paulo, what can we learn from the Housing First model?', *IDPC Blog*, <http://idpc.net/blog/2014/12/bracos-abertos-in-sao-paulo-what-can-we-learn-from-the-housing-first-model>
121. Prefeitura da Cidade de Sao Paulo (2015), *Alcohol and drug policy within the city of Sao Paulo*, presentation delivered at the International Harm Reduction Conference in Kuala Lumpur, Malaysia, October 2015
122. For more information, see: <https://dancesafe.org/drug-checking/>
123. See, for instance: National Post (30 December 2011), *Vancouver health body begins free crack pipe program for addicts*, <http://news.nationalpost.com/news/canada/vancouver-health-body-begins-free-crack-pipe-program-for-addicts>; for best practice guidelines on safer crack smoking equipment distribution, see: Strike, C, Gohil, H. & Watson T.M. (2014), *Safer crack cocaine smoking equipment distribution: Comprehensive best practice guidelines* (Canada's source for HIV and hepatitis C information), <http://www.catie.ca/en/pif/fall-2014/safer-crack-cocaine-smoking-equipment-distribution-comprehensive-best-practice-guideli>
124. United Nations Office on Drugs and Crime (2015), *UNODC World Drug Report 2015*, <http://www.unodc.org/wdr2015/>
125. Ibid
126. National Institute for Health and Clinical Excellence (2007), *Methadone and buprenorphine in the management of opioid dependence* (London: NICE), <https://www.nice.org.uk/guidance/ta114>
127. MacArthur, G.J., et al (October 2012), 'Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis', *British Medical Journal*, **345**: e5945, <http://www.bmj.com/content/345/bmj.e5945>
128. Ibid; As observed by the UNODC, many people dependent on drugs 'who would be motivated to treatment but do not find accessible well equipped treatment facilities in their neighbourhood are de facto condemned to remain in a condition of dependence and to perpetuate their dependence in social exclusion'. See: United Nations Office on Drugs and Crime (2009), *Reducing the adverse health and social consequences of drug abuse: A comprehensive approach*, <https://www.unodc.org/documents/prevention/Reducing-adverse-consequences-drug-abuse.pdf>
129. Godfrey, C., Stewart, D. & Gossop, M. (2004), 'Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS)', *Addiction*, **99**(6): 697–707, <http://cat.inist.fr/?a-Modele=afficheN&cpsidt=15796344>.
130. National Treatment Agency for Substance Misuse (2010), *A long-term study of the outcomes of drug users leaving treatment*, [http://www.nta.nhs.uk/uploads/outcomes\\_of\\_drug\\_users\\_leaving\\_treatment2010.pdf](http://www.nta.nhs.uk/uploads/outcomes_of_drug_users_leaving_treatment2010.pdf)
131. Stimson, G. et al (2010), *Three cents a day is not enough* (London: Harm Reduction International), [http://idpc.net/sites/default/files/library/IHRA\\_3CentsReport.pdf](http://idpc.net/sites/default/files/library/IHRA_3CentsReport.pdf)
132. National Institute on Drug Abuse (2007), *Cost effectiveness of drug treatment*, <https://www.drugabuse.gov/publications/teaching-packets/understanding-drug-abuse-addiction/section-iv/6-cost-effectiveness-drug-treatment>
133. National Institute on Drug Abuse (2006), *International program, methadone research web guide*
134. Botvin, G., Schinke, J. & Steven, P. (1997), *The etiology and prevention of drug abuse among minority youth*. (New York: Haworth Press); Beauvais, F. & LaBoueff, S. (1985), 'Drug and alcohol abuse intervention in American Indian communities', *Substance Use & Misuse*, **20**(1): 139–171, <http://informahealthcare.com/doi/abs/10.3109/10826088509074831>; Davis, R.B. (1994), 'Drug and alcohol use in the former Soviet Union: selected factors and future considerations', *Substance Use & Misuse*, **29**(3): 303–323, <http://informahealthcare.com/doi/abs/10.3109/10826089409047383>.
135. The texts of the 3 UN drug control treaties are available here: <https://www.unodc.org/unodc/en/commissions/CND/conventions.html>

136. Office of the United Nations High Commissioner for Human Rights & World Health Organisation (2008), *The right to health: Fact sheet No. 31* (Geneva: United Nations), <http://www.ohchr.org/Documents/Publications/Factsheet31.pdf>
137. 1961 Single Convention on Narcotic Drugs, <http://www.unodc.org/unodc/en/treaties/single-convention.html> & UN Convention on Psychotropic Drugs of 1971, <https://www.unodc.org/unodc/en/treaties/psychotropics.html>
138. Office of the High Commissioner for Human Rights (2009), *Press release: High Commissioner calls for focus on human rights and harm reduction in international drug policy* (Geneva: Human Rights Council), [http://www.ohchr.org/documents/Press/HC\\_human\\_rights\\_and\\_harm\\_reduction\\_drug\\_policy.pdf](http://www.ohchr.org/documents/Press/HC_human_rights_and_harm_reduction_drug_policy.pdf)
139. World Health Organisation (April 2015), *WHO model list of essential medicines, 19<sup>th</sup> list*, [http://www.who.int/selection\\_medicines/committees/expert/20/EML\\_2015\\_FINAL\\_amended\\_AUG2015.pdf?ua=1](http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1)
140. Human Rights Watch (2007), *Rehabilitation required: Russia's human rights obligation to provide evidence-based drug dependence treatment*, <https://www.hrw.org/report/2007/11/07/rehabilitation-required/russias-human-rights-obligation-provide-evidence-based>
141. Hallam, C. (2010), *IDPC Briefing Paper – Heroin-assisted treatment: The state of play* (London: International Drug Policy Consortium), <http://idpc.net/publications/2010/07/idpc-briefing-heroin-assisted-treatment>
142. Strang J., et al (2010), 'Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial', *The Lancet*, **375**(9729): 1885–1895, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60349-2/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60349-2/abstract)
143. Ibid
144. Strang, J., et al (July 2015), 'Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction', *The British Journal of Psychiatry*, **207**(1): 5-14, <http://bjp.rcpsych.org/content/207/1/5>
145. United Nations Office on Drugs and Crime (2015), *UNODC World Drug Report 2015*, <http://www.unodc.org/wdr2015/>
146. Holt, E. (2010), 'World report: Russian injected drug use soars in the face of political inertia', *The Lancet*, **376**(9734): 13-14, [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)61041-0/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61041-0/fulltext)
147. World Health Organisation Western Pacific Region (2009), *Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: An application of selected human rights principles*, [http://www.who.int/hiv/pub/idu/assess\\_treatment\\_users\\_asia/en/](http://www.who.int/hiv/pub/idu/assess_treatment_users_asia/en/); Pearshouse R. (2009), *Compulsory drug treatment in Thailand: Observations on the Narcotic Addict Rehabilitation Act B.E. 2545 (2002)* (Toronto: Canadian HIV/AIDS Legal Network), <http://www.aidslaw.ca/site/compulsory-drug-treatment-in-thailand-observations-on-the-narcotic-addict-rehabilitation-act-b-e-2545-2002/>; 'Harm Reduction 2009: IHRA's 20<sup>th</sup> International Conference' in Bangkok (21 April 2009): Session on 'Compulsory drug dependence treatment centres: Costs, rights and evidence (supported by the UNODC and the International Harm Reduction Development Program of the Open Society Institute)', <http://www.ihra.net/contents/128>
148. International Harm Reduction Development Programme (2011), *Treated with cruelty: Abuses in the name of drug rehabilitation* (New York: Open Society Foundations), [http://www.soros.org/initiatives/health/focus/ihrd/articles\\_publications/publications/treated-with-cruelty-20110624/treatedwithcruelty.pdf](http://www.soros.org/initiatives/health/focus/ihrd/articles_publications/publications/treated-with-cruelty-20110624/treatedwithcruelty.pdf)
149. Human Rights Watch (2011), *The rehab archipelago: Forced labour and other abuses in drug detention centres in Southern Vietnam*, <http://www.hrw.org/sites/default/files/reports/vietnam-0911ToPost.pdf>
150. Godwin, J. (2016), *A public health approach to drug use in Asia: Principles and practices for decriminalisation* (London: International Drug Policy Consortium), <http://idpc.net/publications/2016/03/public-health-approach-to-drug-use-in-asia-decriminalisation>
- Human Rights Watch (2010), *Where darkness knows no limits: Incarceration, ill-treatment and forced labour as drug rehabilitation in China*, <http://www.hrw.org/reports/2010/01/07/where-darkness-knows-no-limits-0>
151. See: United Nations Office of the High Commissioner for Human Rights, International Labor Organization, United Nations Development Program, UNESCO, United Nations Population Fund, United Nations High Commissioner for Refugees, UNICEF, United Nations Office on Drugs and Crime, UN Women, World Food Programme, World Health Organisation & Joint United Nations Programme on HIV/AIDS (March 2012), *Joint statement: Compulsory drug detention and rehabilitation centres*, [https://dl.dropboxusercontent.com/u/64663568/alerts/Joint-Statement\\_Compulsory-drug-detention-and-rehabilitation-centres.pdf](https://dl.dropboxusercontent.com/u/64663568/alerts/Joint-Statement_Compulsory-drug-detention-and-rehabilitation-centres.pdf)
152. United Nations Programme on HIV/AIDS (23 September 2015), *Press release: New Roadmap to voluntary community-based services for people who use drugs in Asia*, <http://unaids-ap.org/2015/09/23/press-release-new-roadmap-to-voluntary-community-based-services-for-people-who-use-drugs-in-asia/>
153. Tanguay, P., et al (2015), 'Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia' *Harm Reduction Journal*, **12**:31, <http://www.harmreductionjournal.com/content/12/1/31>; Tanguay, P., Stoicescu, C. & Cook, C. (October 2015), *Community-based drug treatment models for people who use drugs*, [http://www.ihra.net/files/2015/10/19/Community\\_based\\_drug\\_treatment\\_models\\_for\\_people\\_who\\_use\\_drugs.pdf](http://www.ihra.net/files/2015/10/19/Community_based_drug_treatment_models_for_people_who_use_drugs.pdf)
154. Case study drawn from: Tanguay, P., Stoicescu, C. & Cook, C. (October 2015), *Community-based drug treatment models for people who use drugs*, [http://www.ihra.net/files/2015/10/19/Community\\_based\\_drug\\_treatment\\_models\\_for\\_people\\_who\\_use\\_drugs.pdf](http://www.ihra.net/files/2015/10/19/Community_based_drug_treatment_models_for_people_who_use_drugs.pdf)
155. National Treatment Agency for Substance Misuse (2012), *Medications in recovery – Re-orientating drug dependence treatment*, <http://www.nta.nhs.uk/uploads/medications-in-recovery-main-report3.pdf>
156. Patterson, K. (10 June 2015), 'A new definition of recovery: Beyond abstinence', *Addiction.com*, <https://www.addiction.com/10687/a-new-definition-of-recovery-beyond-abstinence/>
157. United Nations Office on Drugs and Crime (2011), *Amphetamines and Ecstasy: 2011 Global ATS Report*, [https://www.unodc.org/documents/ATS/ATS\\_Global\\_Assessment\\_2011.pdf](https://www.unodc.org/documents/ATS/ATS_Global_Assessment_2011.pdf)
158. Shearer, J., Sherman, J., Wodak, A. & Van Beek, I. (2002), 'Substitution therapy for amphetamine users', *Drug and Alcohol Review*, **21**: 179-185, <http://www.undrugcontrol.info/en/issues/safer-crack-use/item/4535-substitution-therapy-for-amphetamine-users>
159. Srisurapanont, M., Jarusuraisin, N. & Kittirattanapaiboon, P. (2008), 'Treatment for amphetamine dependence and Abuse', *Database of Systematic Reviews*, Issue 3, <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003022.pub2/epdf>
161. Shearer, J., Sherman, J., Wodak, A. & Van Beek, I. (2002), 'Substitution therapy for amphetamine users', *Drug and Alcohol Review*, **21**: 179-185, <http://www.undrugcontrol.info/en/issues/safer-crack-use/item/4535-substitution-therapy-for-amphetamine-users>
162. Goncalves, J.R. & Nappo, S.A. (July 2015), 'Factors that lead to the use of crack cocaine in combination with marijuana in Brazil: A qualitative study', *BMC Public Health*, **15**: 706, <http://bmcpublihealth.biomedcentral.com/articles/10.1186/s12889-015-2063-0#CR14>; Ribeiro, L.A., Sanchez, Z.M. & Nappo, S.A. (2010), 'Surviving crack: A qualitative study of the strategies and tactics developed by Brazilian users to deal with the risks associated', *BMC Public Health*, **10**: 671, <http://bmcpublihealth.biomedcentral.com/articles/10.1186/1471-2458-10-671>
163. Goncalves, J.R. & Nappo, S.A. (July 2015), 'Factors that lead to the use of crack cocaine in combination with marijuana in Brazil: A qualitative study', *BMC Public Health*, **15**: 706, <http://bmcpublihealth.biomedcentral.com/articles/10.1186/s12889-015-2063-0#CR14>
164. Labigalini, E., Rodrigues, L.R. & Da Silveira, D.X. (1999), 'Therapeutic use of cannabis by crack addicts in Brazil', *Journal of Psychoactive*

*Drugs*, **31**(4): 451-455, [http://druglawreform.info/images/stories/documents/Therapeutic\\_Cannabis\\_Crack\\_Brazil.pdf](http://druglawreform.info/images/stories/documents/Therapeutic_Cannabis_Crack_Brazil.pdf)

165. BBC Mundo (25 March 2013), *Bogotá quiere de aliada a la marihuana*, [http://www.bbc.com/mundo/noticias/2013/03/130322\\_colombia\\_marihuana\\_combate\\_adicciones\\_bogota\\_aw.shtml#reports](http://www.bbc.com/mundo/noticias/2013/03/130322_colombia_marihuana_combate_adicciones_bogota_aw.shtml#reports)



166. Red Iberoamericana de ONGs que trabajan en drogodependencias (9 December 2015), *Hospital de Uruguay impulsa tratar a adictos a pasta base con marihuana*, <http://www.riod.org/noticia.php?idn=1660>